Professor David Burgner is a practising paediatric infectious diseases physician, leads the Inflammatory Origins Group and co-leads the LifeCourse longitudinal observational cohorts initiative at Murdoch Children’s Research Institute. He holds major national and international clinical / research positions including leadership roles in ASID, ESPID, WSPID and is an AAHMS fellow.
Professor Burgner is an international authority on understanding the susceptibility and consequences to childhood infection and inflammation, particularly in relation to the development of cardiometabolic disease risk. He is an internationally recognised clinical and scientific leader in Kawasaki disease and has made major scientific, clinical and policy contributions to the Australian response to the COVID-19 pandemic, particularly the hyperinflammatory post-infectious syndrome (known as PIMS-TS or MIS-C) in children.
Professor David Burgner is a practising paediatric infectious diseases physician, leads the Inflammatory Origins Group and co-leads the LifeCourse longitudinal observational cohorts initiative at Murdoch Children’s Research Institute. He holds major...
Professor David Burgner is a practising paediatric infectious diseases physician, leads the Inflammatory Origins Group and co-leads the LifeCourse longitudinal observational cohorts initiative at Murdoch Children’s Research Institute. He holds major national and international clinical / research positions including leadership roles in ASID, ESPID, WSPID and is an AAHMS fellow.
Professor Burgner is an international authority on understanding the susceptibility and consequences to childhood infection and inflammation, particularly in relation to the development of cardiometabolic disease risk. He is an internationally recognised clinical and scientific leader in Kawasaki disease and has made major scientific, clinical and policy contributions to the Australian response to the COVID-19 pandemic, particularly the hyperinflammatory post-infectious syndrome (known as PIMS-TS or MIS-C) in children.
Top Publications
Nuotio, J, Niiranen, T, Laitinen, TT, Miller, J, Sabin, MA, Havulinna, AS, Viikari, JSA, Rönnemaa, T, Hutri-Kähönen, N, Laitinen, TP, et al.
Use of antibiotics and risk of type 2 diabetes, overweight and obesity: the Cardiovascular Risk in Young Finns Study and the national FINRISK study..
BMC Endocr Disord
22(1)
:
284
2022
view publication
Bekkering, S, Singh, K, Lu, H, Limawan, AP, Nold-Petry, CA, Wallace, MJ, Curtis, N, Pepe, S, Cheung, M, Burgner, DP, et al.
Neonatal Subcutaneous BCG Vaccination Decreases Atherosclerotic Plaque Number and Plaque Macrophage Content in ApoE-/- Mice..
Biology (Basel)
11(10)
:
2022
view publication
O'Connor, M, Moreno-Betancur, M, Goldfeld, S, Wake, M, Patton, G, Dwyer, T, Tang, MLK, Saffery, R, Craig, JM, Loke, J, et al.
Data Resource Profile: Melbourne Children's LifeCourse initiative (LifeCourse)..
Int J Epidemiol
51(5)
:
e229 -e244
2022
view publication
Miller, JE, Burgner, DP.
Commentary: Recognizing subsequent infection risk following hospital discharge among children..
Int J Epidemiol
51(5)
:
1431 -1432
2022
view publication
Lopez, L, Burgner, D, Glover, C, Carr, J, Clark, J, Boast, A, Vasilunas, N, McMullan, B, Francis, JR, Bowen, AC, et al.
Lower risk of Multi-system inflammatory syndrome in children (MIS-C) with the omicron variant..
Lancet Reg Health West Pac
27:
100604
2022
view publication